DNA methylation and gene silencing in cancer (original) (raw)
Bird A (2002) DNA methylation patterns and epigenetic memory. Genes Dev16: 6–21 CASPubMed Google Scholar
Jones PA and Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet3: 415–428 CASPubMed Google Scholar
Herman JG and Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med349: 2042–2054 CASPubMed Google Scholar
Merlo A et al. (1995) 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med1: 686–692 CASPubMed Google Scholar
Leone G et al. (2002) DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica87: 1324–1341 CASPubMed Google Scholar
Daskalakis M et al. (2002) Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′-deoxycytidine (decitabine) treatment. Blood100: 2957–2964 CASPubMed Google Scholar
Ruter B et al. (2004) DNA methylation as a therapeutic target in hematologic disorders: recent results in older patients with myelodysplasia and acute myeloid leukemia. Int J Hematol80: 128–135 PubMed Google Scholar
Galm O et al. (online) The fundamental role of epigenetics in hematopoietic malignancies. Blood Rev, February 2005
Bestor TH (2000) The DNA methyltransferases of mammals. Hum Mol Genet9: 2395–2402 CASPubMed Google Scholar
Herman JG et al. (1998) Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA95: 6870–6875 CASPubMedPubMed Central Google Scholar
Esteller M et al. (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med343: 1350–1354 CASPubMed Google Scholar
Okano M et al. (1999) DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell99: 247–257 CASPubMed Google Scholar
Okano M et al. (1998) Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat Genet19: 219–220 CASPubMed Google Scholar
Rhee I et al. (2002) DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature416: 552–556 CASPubMed Google Scholar
Rhee I et al. (2000) CpG methylation is maintained in human cancer cells lacking DNMT1. Nature404: 1003–1007 CASPubMed Google Scholar
Fuks F et al. (2000) DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat Genet24: 88–91 CASPubMed Google Scholar
Robertson KD et al. (2000) DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat Genet25: 338–342 CASPubMed Google Scholar
Rountree MR et al. (2000) DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat Genet25: 269–277 CASPubMed Google Scholar
Fuks F et al. (2001) Dnmt3a binds deacetylases and is recruited by a sequence-specific repressor to silence transcription. EMBO J20: 2536–2544 CASPubMedPubMed Central Google Scholar
Bachman KE et al. (2001) Dnmt3a and Dnmt3b are transcriptional repressors that exhibit unique localization properties to heterochromatin. J Biol Chem276: 32282–32287 CASPubMed Google Scholar
Jenuwein T and Allis CD (2001) Translating the histone code. Science293: 1074–1080 CASPubMed Google Scholar
Bannister AJ et al. (2001) Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. Nature410: 120–124 CASPubMed Google Scholar
Nakayama J et al. (2001) Role of histone H3 lysine 9 methylation in epigenetic control of heterochromatin assembly. Science292: 110–113 CASPubMed Google Scholar
Noma K et al. (2001) Transitions in distinct histone H3 methylation patterns at the heterochromatin domain boundaries. Science293: 1150–1155 CASPubMed Google Scholar
Bird AP and Wolffe AP (1999) Methylation-induced repression-belts, braces, and chromatin. Cell99: 451–454 CASPubMed Google Scholar
Marks PA et al. (2000) Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst92: 1210–1216 CASPubMed Google Scholar
Mei S et al. (2004) Role of histone deacetylase inhibitors in the treatment of cancer. Int J Oncol25: 1509–1519 CASPubMed Google Scholar
Drummond DC et al. (2005) Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol45: 495–528 CASPubMed Google Scholar
Cameron EE et al. (1999) Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet21: 103–107 CASPubMed Google Scholar
Suzuki H et al. (2002) A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet31: 141–149 CASPubMed Google Scholar
Knudson AG (2001) Two genetic hits (more or less) to cancer. Nat Rev Cancer1: 157–162 CASPubMed Google Scholar
Esteller M et al. (2001) DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet10: 3001–3007 CASPubMed Google Scholar
Grady WM et al. (2000) Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat Genet26: 16–17 CASPubMed Google Scholar
Herman JG (1999) Hypermethylation of tumor suppressor genes in cancer. Semin Cancer Biol9: 359–367 CASPubMed Google Scholar
Herman JG et al. (1994) Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA91: 9700–9704 CASPubMedPubMed Central Google Scholar
Bender CM et al. (1998) DNA methylation as a target of drug design. Pharmaceut Res15: 175–187 CAS Google Scholar
Santini V et al. (2001) Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med134: 573–586 CASPubMed Google Scholar
Herman JG et al. (1997) Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res57: 837–841 CASPubMed Google Scholar
Christiansen DH et al. (2003) Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia17: 1813–1819 CASPubMed Google Scholar
Wales MM et al. (1995) p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nat Med1: 570–577 CASPubMed Google Scholar
Chen W et al. (2004) Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis. Cancer Cell6: 387–398 CASPubMed Google Scholar
Chen WY et al. (2003) Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors. Nat Genet33: 197–202 CASPubMed Google Scholar
Glover AB and Leyland-Jones B (1987) Biochemistry of azacitidine: a review. Cancer Treat Rep71: 959–964 CASPubMed Google Scholar
Robertson KD and Jones PA (2000) DNA methylation: past, present and future directions. Carcinogenesis21: 461–467 CASPubMed Google Scholar
Juttermann R et al. (1994) Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci USA91: 11797–11801 CASPubMedPubMed Central Google Scholar
Silverman LR (2001) Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS). Oncologist6: 8–14 CASPubMed Google Scholar
Creusot F et al. (1982) Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacitidine and 5-aza-2′-deoxycytidine. J Biol Chem257: 2041–2048 CASPubMed Google Scholar
Goffin J and Eisenhauer E (2002) DNA methyltransferase inhibitors—state of the art. Ann Oncol13: 1699–1716 CASPubMed Google Scholar
Aparicio A and Weber JS (2002) Review of the clinical experience with 5-azacytidine and 5-aza-2′-deoxycytidine in solid tumors. Curr Opin Investig Drugs3: 627–633 CASPubMed Google Scholar
Luebbert M (2000) DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action. Curr Top Microbiol Immunol249: 135–164 Google Scholar